Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
GlycoAla
London, United Kingdomglycoala.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
GlycoAla is an aesthetic biotechnology company specializing in advanced photodynamic therapy (PDT) for skin rejuvenation and dermatological conditions. The company's flagship product is a unique, light-activated cosmetic gel that utilizes a glycoconjugated form of 5-aminolevulinic acid (5-ALA) encapsulated in nanoparticles. This proprietary delivery system is designed to enhance skin absorption and stability while minimizing the side effects typically associated with traditional PDT. GlycoAla's treatments are used by skincare professionals to address signs of aging, sun damage, and pore appearance, positioning the company at the intersection of medical aesthetics and biotechnology.
- Therapeutic areas
- NephrologyDermatology
- Modalities
- Small moleculeNanoparticlePhotodynamic therapy
- Industry
- Non-Drug Biotech
Beyond the preview
Go deeper on GlycoAla.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GlycoAla.